

本期目录 | 下期目录 | 过刊浏览 | 高级检索

[打印本页] [关闭]

论著

BRAF干扰对甲状腺癌SW579细胞系的影响

易文君, 钟德卉, 邹琼艳

中南大学湘雅二院普外科, 长沙 410011

摘要: 目的: 研究BRAF干扰对甲状腺癌SW579细胞系的影响。方法: 设计合成了2对siRNA干扰序列, 脂质体转染进入甲状腺癌SW579细胞, 采用RT-PCR检测干扰的效果。对干扰成功的细胞系, 检测细胞增殖、细胞周期和丝裂原活化蛋白/细胞外信号调节激酶(mitogen-activated protein signal-regulated kinase/extracellular signal-regulated kinase, MEK/ERK)信号通路相关蛋白的变化。结果: 2种siRNA转染甲状腺癌SW579细胞系后, 显著地抑制了BRAF mRNA及蛋白水平的表达($P<0.01$), SW579的生长增殖受到抑制, 细胞周期发生改变, G_1/S 期增加, 同时, MEK/ERK信号通路的激活受到抑制。结论: 干扰BRAF可能通过失活MEK/ERK信号通路而抑制SW579 细胞系的生长和增殖。

关键词: BRAF RNA干扰 甲状腺癌 MEK/ERK

Influence of BRAF interference on SW579 cell lines in thyroid cancer

YI Wenjun, ZHONG Dewu, ZOU Qiongyan

Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China

Abstract: Objective: To determine the influence of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) interference on SW579 cell lines in thyroid cancer.

Methods: We designed 2 pairs of siRNA interference sequences, transfected them into SW579 cell line with liposome, and detected the interference with RT-PCR method. For successfully interfered cell lines, the changes in cell proliferation, cell cycle, and the expression of related proteins in mitogen-activated protein signal-regulated kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathway were detected.

Results: After 2 pairs of siRNA transfection, the expressions of BRAF mRNA and protein of SW579 cell lines were significantly inhibited ($P<0.01$). The proliferation was inhibited, the cell cycle was changed, G_1/S phase increased, and MEK/ERK signal pathway was inhibited.

Conclusion: Inhibition of growth and proliferation of SW579 cell lines by BRAF may be functioned by deactivating MEK/ERK signal pathway.

Keywords: BRAF RNA interference thyroid carcinoma MEK/ERK

收稿日期 2012-10-07 修回日期 网络版发布日期

DOI: 10.3969/j.issn.1672-7347.2013.06.005

基金项目:

湖南省发展与改革委员会资助项目(2009-1390)。

通讯作者: 易文君, Email: yiwenjun@cscu.org.cn

作者简介: 易文君, 博士, 副教授, 主要从事乳腺甲状腺疾病临床和科研工作。

作者Email: yiwenjun@cscu.org.cn

参考文献:

1. 易文君, 钟德卉, 邹琼燕. BRAF基因突变与甲状腺乳头状瘤的相关性 [J]. 中南大学学报: 医学版, 2012, 37(4): 370-373. YI Wenjun, ZHONG Dewu, ZOU Qiongyan. BRAF mutation and papillary thyroid cancer [J]. Journal of Central South University.Medical Science, 2012, 37(4): 370-373.
2. Howell GM, Nikiforova MN, Carty SE, et al. BRAF^{V600E} mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer [J]. Ann Surg Oncol, 2013, 20(1): 47-52.
3. Prescott JD, Sadow PM, Hodin, et al. BRAF^{V600E} status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence [J]. Surgery, 2012, 152(6): 984-990.
4. Hyeyim J, Sookkim E, Hyun-Jung C, et al. Association between STAT1 activity and BRAF mutations in

扩展功能

本文信息

► Supporting info

► PDF(1518KB)

► [HTML全文]

► 参考文献[PDF]

► 参考文献

服务与反馈

► 把本文推荐给朋友

► 加入我的书架

► 加入引用管理器

► 引用本文

► Email Alert

► 文章反馈

► 浏览反馈信息

本文关键词相关文章

► BRAF

► RNA干扰

► 甲状腺癌

► MEK/ERK

本文作者相关文章

► 易文君

► 钟德卉

► 邹琼艳

PubMed

► Article by YI Wenjun

► Article by ZHONG Dewu

► Article by ZOU Qiongyan

- papillary thyroid carcinomas [J]. J Surg Oncol, 2012, 106(6): 719-723.
5. Ralph P, Justin TB, Gaosong W, et al. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: Efficacy, safety, and the association of the BRAF mutation [J]. Laryngoscope, 2012, 122(7): 1634-1640.
6. Howell G, Carty S, Armstrong MJ, et al. Both BRAF^{V600E} mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer [J]. Ann Surg Oncol, 2011, 18(13): 3566-3571.
7. 易文君, 钟德卉, 邹琼燕. BRAF 及其细胞外信号调节激酶1/2 信号通路蛋白在甲状腺乳头状癌中的表达及意义 [J]. 中南大学学报: 医学版, 2012, 37(9): 891-894. YI Wenjun, ZHONG Dewu, ZOU Qiongyan. Expression of BRAF and its extracellular signal-regulated kinase 1/2 signal pathway in papillary thyroid cancer [J]. Journal of Central South University. Medical Science, 2012, 37(9): 891-894.
8. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia [J]. Science, 1985, 230(10): 1350-1354.
9. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays [J]. J Immunol Methods, 1983, 65(1): 55-63.
10. Towbin H, Staehelin T, Gordon J, et al. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications [J]. Biotechnology, 1992, 24(2): 145-149.
11. Pellicciari C, Manfredi AA, Bottone MG, et al. A single-step staining procedure for the detection and sorting of unfixed apoptotic thymocytes [J]. Eur J Histochem, 1993, 37(4): 381-390.
12. Voinnet O, Baulcombe DC. Systemic signalling in gene silencing [J]. Nature, 1997, 389(6651): 553-559.
13. Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants [J]. Science, 1999, 286(5441): 950-952.
14. Hammond SM, Bernstein E, Beach D, et al. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells [J]. Nature, 2000, 404(6775): 293-296.
15. Zamore PD, Tuschl T, Sharp PA, et al. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals [J]. Cell, 2000, 101(1): 25-33.
16. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice [J]. Cancer Cell, 2009, 15(4): 294-303.
17. Dankort D, Curley DP, Cartlidge RA, et al. Braf^{V600E} cooperates with PTEN loss to induce metastatic melanoma [J]. Nat Genet, 2009, 41(5): 544-552.
18. Ikenoue T, Hikiba Y, Kanai F, et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors [J]. Cancer Res, 2003, 63(23): 8132-8137.
19. Salvatore G, De FV, Salemo P, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma [J]. Clin Cancer Res, 2006, 12(5): 1623-1629.
20. Yang OB, Knauf JA, Smith EP, et al. Inhibitors of raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo [J]. Clin Cancer Res, 2006, 12(6): 1785-1793.

本刊中的类似文章

1. 何艳, 贺兴鄂, 孙会卿, 王文龙, 雷建华. RNA干扰HBx基因对肝癌细胞化疗效果的影响[J]. 中南大学学报(医学版), 2009, 34(05): 395-400
2. 任勇亚. RNA干扰抑制MDR1表达并逆转Bel-1/402/b-Fu肝癌细胞耐药性的研究[J]. 中南大学学报(医学版), 2006, 31(06): 872-876
3. 王云姣, 程智刚, 于鹏, 李靖贻, 白念岳, 贺正华, 杨胜辉, 郭曲练.

携带DREAM基因shRNA的慢病毒载体的构建及其对坐骨神经缩窄损伤大鼠的镇痛作用

- [J]. 中南大学学报(医学版), 2009, 34(08): 723-730
4. 段绍斌, 刘伏友, 陈愔音, 刘芳, 李莹, 凌光辉, 肖力, 刘虹, 彭佑铭. 转化生长因子&bgr;1短发夹RNA对白蛋白致人肾小管上皮细胞细胞因子表达的抑制作用[J]. 中南大学学报(医学版), 2009, 34(10): 949-956
5. 刘惠宁1, 蔡净亭1, 林秋华2, 何可人1, 余蓉1. Caveolin-1与绒毛膜癌侵袭力之间的关系[J]. 中南大学学报(医学版), 2008, 33(04): 331-337
6. 汤天凤1, 周巧玲1, 朱丽丽2, 唐荣1, 敖翔1. 福辛普利、氯沙坦对肾小管上皮细胞TLR4表达的影响[J]. 中南大学学报(医学版), 2008, 33(10): 958-965
7. 张东山1,2, 刘伏友 1, 彭佑铭1, 熊关钟2, 柴湘平2. 抑制Smad3的pSUPER RNAi系统的构建和活性鉴定[J]. 中南大学学报(医学版), 2007, 32(06): 1042-1046
8. 杨晓苏, 胡益民, 肖波, 杨期东, 赵惠敏. 利用RNAi建立脊髓性肌萎缩症的细胞模型[J]. 中南大学学报(医学版), 2008, 33(12): 1108-1112
9. 张勇, 杨欢, 肖波, 鲁特飞. RelB基因沉默的髓源树突状细胞负载Ta146~162对TACR预致敏T细胞免疫反应的影响[J]. 中南大学学报(医学版), 2010, 35(1): 38-44
10. 吕辉, 贺智敏*. RNA干扰技术的演进及其在基因功能和基因治疗研究中的应用[J]. 中南大学学报(医学版), 0(): 102-105
11. 吕辉, 贺智敏*. RNA干扰技术的演进及其在基因功能和基因治疗研究中的应用[J]. 中南大学学报(医学版), 2005, 30(1): 102-105

12. 刘虹1, 2, 刘伏友1, 2, *, 彭佑铭1, 2, 袁芳1, 2, 刘映红1, 2.pcDU6质粒载体介导的TGF β 1
shRNA抑制TGF β 1在人腹膜间皮细胞中的表达[J]. 中南大学学报(医学版), 2004, 29(5): 552-557
13. 李鸿涛, 任光辉, 董朝, 阿力比亚提·艾尼, 马斌林.桥本氏甲状腺炎合并甲状腺癌54例临床研究[J]. 中南大学
学报(医学版), 2011, 36(8): 765-767
14. 易文君, 钟德卉, 邹琼燕.BRAF基因突变与甲状腺乳头状瘤的相关性[J]. 中南大学学报(医学版), 2012, 37(4):
370-373
15. 易文君, 钟德卉, 邹琼燕.BRAF及其细胞外信号调节激酶1/2信号通路蛋白在甲状腺乳头状瘤中的表达及意义
[J]. 中南大学学报(医学版), 2012, 37(9): 889-894

Copyright by 中南大学学报(医学版)